Wat is de prijs voor GenSight Biologics S.A. (SIGHT)

Het prijs van GenSight Biologics S.A. (SIGHT) is $0.12857922

Wat is de marktkapitalisatie voor GenSight Biologics S.A. (SIGHT)

Marktkapitalisatie voorGenSight Biologics S.A. (SIGHT) is $20.96M

GenSight Biologics S.A. (SIGHT) Aandelensplitsingen

GenSight Biologics S.A. is a clinical-stage biotechnology firm focused on identifying, advancing, and commercializing medical interventions for severe mitochondrial and neurodegenerative conditions affecting both the eyes and the central nervous system. Their therapeutic development leverages cutting-edge gene therapy platforms, specifically those involving mitochondrial targeting sequences and optogenetics. The company's leading drug candidate, LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, is currently undergoing Phase III clinical evaluation for treating Leber hereditary optic neuropathy (LHON) caused by a specific ND4 gene mutation. Another significant program, GS030, is engaged in Phase I/II clinical trials for retinitis pigmentosa and is also in the preclinical phase for dry age-related macular degeneration. Furthermore, GenSight Biologics is developing additional preclinical-stage programs aimed at various ophthalmic and neurodegenerative disorders. The company was founded in 2012 and maintains its headquarters in Paris, France.

Jaar	Splitsing	Vermenigvuldiging	Cumulatieve vermenigvuldiging
Niet genoeg gegevens voor de verstrekte datums.

Jaar

Splitsing

Vermenigvuldiging

Cumulatieve vermenigvuldiging

Niet genoeg gegevens voor de verstrekte datums.

Bedrijf	Aantal aandelen splitsingen	Cumulatieve vermenigvuldiging	Land
Vertex Pharmaceuticals Incorporated VRTX.US	1	x2	US
Argenx SE ARGX.US	0	-	NL
CSL Limited CSL.AX	1	x3	AU
Lonza Group AG LONN.SW	0	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0	-	KR

Bedrijf

Aantal aandelen splitsingen

Cumulatieve vermenigvuldiging

Land